Homepage
Catalog of Screening Compounds Screening Libraries Focused and Target Libraries Active Reference Sets Diversity Libraries
Screening Compounds Building blocks
Drug Discovery Services Custom Chemistry Medicinal chemistry In silico Drug Design (CADD) Discovery Biology Animal Models Toxicology and Safety ADME, DMPK Chemistry, Manufacturing and Controls
Company News & Media Contact us For suppliers Trends in discovery compounds
Homepage > Company > Media > Pharma News > 2022

Pharma News, 2022

FDA Approves Hyftor (sirolimus topical gel) for Facial Angiofibroma Associated with Tuberous Sclerosis
FDA Approves Hyftor (sirolimus topical gel) for Facial Angiofibroma Associated with Tuberous Sclerosis
Nobelpharma America, LLC, a pharmaceutical and medical device company headquartered in Bethesda, Maryland, and a subsidiary of Nobelpharma Co., Ltd. in Tokyo, today announced that the U.S. Food an...
BioXcel’s Schizophrenia and Bipolar-Associated Agitation Drug Approved
BioXcel’s Schizophrenia and Bipolar-Associated Agitation Drug Approved
BioXcel Therapeutics has gained the FDA’s approval for Igalmi, its sublingual film formulation of dexmedetomidine, for the treatment of agitation associated with schizophrenia or bipolar disorder...
AstraZeneca’s AZD8233 Shows Positive Results for Hypercholesterolemia
AstraZeneca’s AZD8233 Shows Positive Results for Hypercholesterolemia
AZD8233, an investigational antisense oligonucleotide (ASO), met the primary endpoint at 50 mg with 73% reduction in low-density lipoprotein cholesterol (LDL-C) levels from baseline in the ETESIAN...
China Kintor's COVID drug candidate cuts hospital, death risk in trial
China Kintor's COVID drug candidate cuts hospital, death risk in trial
China's Kintor Pharmaceutical  said on Wednesday its potential COVID-19 treatment proxalutamide effectively reduced the risk of hospitalization and death in a clinical trial involving outpati...
Theravance’s Investigational Drug Ampreloxetine Fails Second Phase 3 Trial
Theravance’s Investigational Drug Ampreloxetine Fails Second Phase 3 Trial
Theravance Biopharma said that its investigational drug ampreloxetine failed its second phase 3 study in patients with symptomatic neurogenic orthostatic hypotension, a condition that frequently i...
African clinical trial denied access to key COVID drug Paxlovid
African clinical trial denied access to key COVID drug Paxlovid
Supply shortages and limits on research leave low- and middle-income countries struggling to access Pfizer’s COVID-19 antiviral. ...
Alnylam's Onpattro follow-on delayed thanks to manufacturing holdup at FDA
Alnylam's Onpattro follow-on delayed thanks to manufacturing holdup at FDA

Alnylam must wait a few months longer for a verdict on its potential blockbuster-in-waiting vutrisiran.

How did Merck record an 11% tax rate last year? The Senate finance chairman would like to know
How did Merck record an 11% tax rate last year? The Senate finance chairman would like to know

With tax day right around the corner in the U.S., Merck & Co. is the latest Big Pharma to find itself in the crosshairs of a congressional tax probe.

EU Approves Immunocore’s Kimmtrak for Patients With Unresectable/Metastatic Uveal Melanoma
EU Approves Immunocore’s Kimmtrak for Patients With Unresectable/Metastatic Uveal Melanoma
The European Commission has approved Immunocore’s T-cell receptor (TCR) bispecific immunotherapy drug Kimmtrak (tebentafusp) for HLA-A*02:01-positive adult patients with unresectable or metastat...
FDA Puts Emavusertib Clinical Trial for R/R AML and MDS on Partial Hold
FDA Puts Emavusertib Clinical Trial for R/R AML and MDS on Partial Hold
The FDA has placed a partial hold on Curis’ phase 1/2a clinical trial of emavusertib in adult patients with relapsed/refractory (R/R) acute myelogenous leukemia (AML) or high-risk myelodysplasti...
Researchers Harness Probiotics to Deliver Parkinson’s Disease Treatment
Researchers Harness Probiotics to Deliver Parkinson’s Disease Treatment

Animal studies show live biotherapeutic produced by gut-healthy probiotic bacteria is safe, reduces treatment complications.

A million times faster: DNA nanotechnology could speed up pharmaceutical development while minimizing costs
A million times faster: DNA nanotechnology could speed up pharmaceutical development while minimizing costs

A new tool speeds up development of vaccines and other pharmaceutical products by more than 1 million times while minimizing costs.

Catalog of Screening Compounds Screening Libraries Screening Compounds Building blocks
Drug Discovery Services News & Media Contact us
Payment systems
Policies & Terms     ©2023 ChemDiv     ChemistryOnDemand